New hope for kids with transplant complication: belumosudil trial launches
NCT ID NCT07116031
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug belumosudil in children aged 1 to 18 who have moderate-to-severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and whose condition has not improved with at least two prior treatments. The trial has two phases: the first finds the right dose for younger children, and the second checks how well the drug works and how safe it is. About 37 children will take part, and the study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belumosudil (also known as Rezurock)
What this could lead to
If successful, this could provide a new treatment option for children with chronic graft-versus-host disease who have not responded to other therapies.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply to all children. The drug may cause side effects or fail to improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Los Angeles- Site Number : 8400009
RECRUITINGLos Angeles, California, 90027, United States
-
Children's National Medical Center - Washington- Site Number : 8400005
RECRUITINGWashington D.C., District of Columbia, 20010, United States
-
Fred Hutchinson Cancer Research Center- Site Number : 8400002
RECRUITINGSeattle, Washington, 98109, United States
-
Investigational Site Number : 0560001
RECRUITINGLeuven, 3000, Belgium
-
Investigational Site Number : 0560003
RECRUITINGGhent, 9000, Belgium
-
Investigational Site Number : 1240001
RECRUITINGVancouver, British Columbia, V6H 3N1, Canada
-
Investigational Site Number : 1240002
RECRUITINGToronto, Ontario, M5G 1X8, Canada
-
Investigational Site Number : 1560001
RECRUITINGShanghai, 200040, China
-
Investigational Site Number : 1560002
RECRUITINGSuzhou, 215025, China
-
Investigational Site Number : 1560003
RECRUITINGBeijing, 100045, China
-
Investigational Site Number : 1560004
RECRUITINGShenzhen, 518026, China
-
Investigational Site Number : 2500001
RECRUITINGParis, 75019, France
-
Investigational Site Number : 2500002
RECRUITINGMarseille, 13885, France
-
Investigational Site Number : 2760001
RECRUITINGBerlin, 13353, Germany
-
Investigational Site Number : 3760001
RECRUITINGTel Aviv, 6423906, Israel
-
Investigational Site Number : 3760002
RECRUITINGJerusalem, 9112001, Israel
-
Investigational Site Number : 3760003
RECRUITINGRamat Gan, 5262100, Israel
-
Investigational Site Number : 3760004
RECRUITINGPetah Tikva, 4920235, Israel
-
Investigational Site Number : 3760005
RECRUITINGHaifa, 3109601, Israel
-
Investigational Site Number : 3800001
RECRUITINGRome, Roma, 00165, Italy
-
Investigational Site Number : 3800002
RECRUITINGMilan, Milano, 20122, Italy
-
Investigational Site Number : 3800003
RECRUITINGTurin, Torino, 10126, Italy
-
Investigational Site Number : 3920002
RECRUITINGTokyo, 157-8535, Japan
-
Investigational Site Number : 5280001
RECRUITINGUtrecht, 3584 CS, Netherlands
-
Investigational Site Number : 7240001
RECRUITINGBarcelona, 08035, Spain
-
Investigational Site Number : 7240002
RECRUITINGMadrid, 28009, Spain
-
Investigational Site Number : 7240003
RECRUITINGEsplugues de Llobregat, Barcelona [Barcelona], 08950, Spain
-
Investigational Site Number : 7920001
RECRUITINGIzmir, 35100, Turkey (Türkiye)
-
Investigational Site Number : 7920003
RECRUITINGAnkara, 06800, Turkey (Türkiye)
-
Investigational Site Number : 8260001
RECRUITINGLondon, London, City of, WC1N 3JH, United Kingdom
-
Investigational Site Number : 8260002
RECRUITINGNewcastle upon Tyne, England, NE2 4HH, United Kingdom
-
Memorial Sloan Kettering Cancer Center - New York - York Avenue- Site Number : 8400001
RECRUITINGNew York, New York, 10065, United States
-
Texas Children's Hospital- Site Number : 8400008
RECRUITINGHouston, Texas, 77030, United States